PA8 Paion AG

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that it will be present at the following conferences:

Rodman & Renshaw Annual Global Investment ConferenceDate: Friday, 11 September, 2009Time: 10:00 a.m. EDT (04:00 p.m. CEST, 03:00 p.m. BST)Venue: New York, USAPresenter: Dr. Wolfgang S�hngen, CEO of PAION AG

German Healthcare ConferenceOrganizer: DZ Bank with Deutsche B�rse GroupDate: Friday, 11 September, 2009Time: 09:50 a.m. CEST (03:50 a.m. EDT, 08:50 a.m. BST)Venue: Zurich, SwitzerlandPresenter: Dr. Mariola S�hngen, CMO of PAION AG

UBS Global Life Sciences ConferenceDate: Tuesday, 22 September, 2009Time: 11:30 a.m. EDT (05:30 p.m. CEST, 04:30 p.m. BST)Venue: New York, USAPresenter: Dr. Wolfgang S�hngen, CEO of PAION AG

Bio Europe 2009Date: 2-4 November 2009Time: N/AVenue: Vienna, AustriaPresenter: To Be Announced

German Equity Forum Fall 2009Date: Tuesday, 10 November, 2009Time: 03:45 p.m. CET in Room Zurich (09:45 a.m. ET, 02:45 p.m. GMT)Venue: Frankfurt/Main, GermanyPresenters: Dr. Wolfgang S�hngen, CEO of PAION AGBernhard Hofer, CFO of PAION AG

###

About PAION PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specialized in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION has a “Search & Develop” business model, which is based on its core expertise in drug development. Where appropriate, particularly during the late stages of the clinical development, PAION seeks to collaborate with experienced partners.

Paion (TG:PA8)
Historical Stock Chart
From Oct 2024 to Nov 2024

Paion (TG:PA8)
Historical Stock Chart
From Nov 2023 to Nov 2024